Overview

Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fasted Conditions

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Irbesartan 300 mg Tablets under fasted conditions
Phase:
N/A
Details
Lead Sponsor:
Roxane Laboratories
Treatments:
Irbesartan